Stereotactic Body Radiotherapy Viable Alternative for Localized Prostate Cancer
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- Stereotactic body radiotherapy (SBRT) is noninferior to conventional or moderately fractionated radiotherapy for localized prostate cancer (PC), according to a study published online Oct. 16 in the New England Journal of Medicine.
Nicholas van As, from the Royal Marsden Hospital in London, and colleagues assessed whether SBRT is noninferior to conventionally or moderately hypofractionated regimens in patients with localized PC. The analysis included patients randomly assigned to SBRT (36.25 Gy in five fractions over one or two weeks) or control radiotherapy (78 Gy in 39 fractions over 7.5 weeks or 62 Gy in 20 fractions over four weeks).
The researchers found that at a median follow-up of 74.0 months, the five-year incidence of freedom from biochemical or clinical failure was 95.8 percent in the SBRT group and 94.6 percent in the control radiotherapy group (unadjusted hazard ratio for biochemical or clinical failure, 0.73; 90 percent confidence interval, 0.48 to 1.12; P = 0.004 for noninferiority). The cumulative incidence of late Radiation Therapy Oncology Group (RTOG) grade ≥2 genitourinary toxic effects at five years was 26.9 percent with SBRT and 18.3 percent with control radiotherapy (P < 0.001). For RTOG grade ≥2 gastrointestinal toxic effects, the cumulative incidence was 10.7 percent and 10.2 percent, respectively (P = 0.94).
“Five-fraction SBRT is a robust and viable alternative to moderately fractionated radiotherapy for prostate cancer, offering equivalent efficacy with enhanced convenience for patients,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.